JP4712966B2 - 単純ヘルペスウイルス侵入メディエーターのためのリガンドおよびその使用方法 - Google Patents

単純ヘルペスウイルス侵入メディエーターのためのリガンドおよびその使用方法 Download PDF

Info

Publication number
JP4712966B2
JP4712966B2 JP2000502082A JP2000502082A JP4712966B2 JP 4712966 B2 JP4712966 B2 JP 4712966B2 JP 2000502082 A JP2000502082 A JP 2000502082A JP 2000502082 A JP2000502082 A JP 2000502082A JP 4712966 B2 JP4712966 B2 JP 4712966B2
Authority
JP
Japan
Prior art keywords
polypeptide
hvem
cells
ltβr
pma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2000502082A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001509373A5 (cg-RX-API-DMAC7.html
JP2001509373A (ja
Inventor
ウェア・カール・エフ
Original Assignee
ラ ホヤ インスティチュート フォー アラジー アンド イムノロジー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ラ ホヤ インスティチュート フォー アラジー アンド イムノロジー filed Critical ラ ホヤ インスティチュート フォー アラジー アンド イムノロジー
Publication of JP2001509373A publication Critical patent/JP2001509373A/ja
Publication of JP2001509373A5 publication Critical patent/JP2001509373A5/ja
Application granted granted Critical
Publication of JP4712966B2 publication Critical patent/JP4712966B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C07K14/5255—Lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
JP2000502082A 1997-07-07 1998-07-07 単純ヘルペスウイルス侵入メディエーターのためのリガンドおよびその使用方法 Expired - Fee Related JP4712966B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US5196497P 1997-07-07 1997-07-07
US08/898,234 1997-07-30
US60/051,964 1997-07-30
US08/898,234 US6140467A (en) 1997-07-07 1997-07-30 Ligand for herpes simplex virus entry mediator and methods of use
PCT/US1998/013897 WO1999002563A1 (en) 1997-07-07 1998-07-07 Ligand for herpes simplex virus entry mediator and methods of use

Publications (3)

Publication Number Publication Date
JP2001509373A JP2001509373A (ja) 2001-07-24
JP2001509373A5 JP2001509373A5 (cg-RX-API-DMAC7.html) 2006-01-05
JP4712966B2 true JP4712966B2 (ja) 2011-06-29

Family

ID=26730006

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000502082A Expired - Fee Related JP4712966B2 (ja) 1997-07-07 1998-07-07 単純ヘルペスウイルス侵入メディエーターのためのリガンドおよびその使用方法

Country Status (11)

Country Link
US (1) US6140467A (cg-RX-API-DMAC7.html)
EP (1) EP1003782B1 (cg-RX-API-DMAC7.html)
JP (1) JP4712966B2 (cg-RX-API-DMAC7.html)
KR (1) KR100620334B1 (cg-RX-API-DMAC7.html)
CN (2) CN1891714B (cg-RX-API-DMAC7.html)
AT (1) ATE495240T1 (cg-RX-API-DMAC7.html)
AU (1) AU741419B2 (cg-RX-API-DMAC7.html)
CA (1) CA2296737C (cg-RX-API-DMAC7.html)
DE (1) DE69842096D1 (cg-RX-API-DMAC7.html)
TW (1) TWI222453B (cg-RX-API-DMAC7.html)
WO (1) WO1999002563A1 (cg-RX-API-DMAC7.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6635743B1 (en) 1996-03-22 2003-10-21 Human Genome Sciences, Inc. Apoptosis inducing molecule II and methods of use
US6479254B2 (en) 1996-03-22 2002-11-12 Human Genome Sciences, Inc. Apoptosis inducing molecule II
US6495520B2 (en) 1996-03-22 2002-12-17 Human Genome Sciences, Inc. Apoptosis Inducing Molecule II and methods of use
US7964190B2 (en) 1996-03-22 2011-06-21 Human Genome Sciences, Inc. Methods and compositions for decreasing T-cell activity
US6998108B1 (en) 1997-07-07 2006-02-14 La Jolla Institute For Allergy And Immunology Antibodies to p30 polypeptides and methods making and using same
US7118742B2 (en) * 1997-07-07 2006-10-10 La Jolla Institute For Allergy And Immunology Ligand for herpes simplex virus entry mediator and methods of use
WO2000010591A1 (en) * 1998-08-18 2000-03-02 The Trustees Of The University Of Pennsylvania Peptides for inhibition of herpes simplex virus entry
WO2001079496A2 (en) * 2000-03-13 2001-10-25 La Jolla Institute For Allergy And Immunology Ligand for herpes simplex virus entry mediator and methods of use
AU2007201279B2 (en) * 2000-03-13 2011-05-26 La Jolla Institute For Allergy And Immunology Ligand for herpes simplex virus entry mediator and methods of use
ATE365214T1 (de) 2000-04-12 2007-07-15 Jolla Inst Allergy Immunolog Ligand des zelleintritt-vermittelnden proteins von herpes simplex und methoden zu dessen verwendungen
WO2002032463A1 (en) * 2000-10-18 2002-04-25 Smithkline Beecham Corporation Methods of treating cancers by stimulating dendritic cells or lymphomas with certain tnf molecules
US7514407B2 (en) * 2002-03-04 2009-04-07 Nymox Corporation Spheron component peptides and pharmaceutical compositions
US7811983B2 (en) * 2003-06-11 2010-10-12 The University Of Chicago Increased T-cell tumor infiltration and eradication of metastases by mutant light
ATE382372T1 (de) * 2003-06-11 2008-01-15 Univ Chicago Erhöhte t-zell tumor-eindringung durch light- mutanten
EP2484696B1 (en) 2006-08-28 2017-08-16 Kyowa Hakko Kirin Co., Ltd. Antagonistic hLIGHT-specific human monoclonal antibodies
WO2008098183A2 (en) * 2007-02-08 2008-08-14 The University Of Chicago Combination therapy for treating cancer
JP2012507299A (ja) * 2008-10-31 2012-03-29 バイオジェン・アイデック・エムエイ・インコーポレイテッド Light標的分子およびその使用
GB201701194D0 (en) 2017-01-24 2017-03-08 Capella Bioscience Ltd Antigen binding molecules that bind light
CN107213456B (zh) * 2017-05-25 2020-08-21 苏州华测生物技术有限公司 淋巴毒素衍生物的新用途
US11312781B2 (en) 2018-01-24 2022-04-26 Capella Bioscience Ltd. Antigen binding molecules that bind LIGHT
WO2019238966A1 (en) * 2018-06-15 2019-12-19 Universität Bern LIGANDS TO LIGHT OR ITS RECEPTOR LTßR FOR USE IN HAEMATOLOGIC MALIGNANCIES
CA3173873A1 (en) 2020-04-01 2021-10-07 Avalo Therapeutics, Inc. Methods and treatment involving excess free light
CN112511569B (zh) * 2021-02-07 2021-05-11 杭州筋斗腾云科技有限公司 网络资源访问请求的处理方法、系统及计算机设备

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ298711B6 (cs) * 1995-01-26 2008-01-02 Biogen Idec Ma Inc. Farmaceutické prostredky aktivující LT-beta receptor pro lécení nebo omezení pokracování, závažnosti nebo úcinku neoplazie, zpusob selekce LT-beta receptor aktivujícího cinidla a protilátky proti LT-beta receptoru
AU2363695A (en) * 1995-04-27 1996-11-18 Human Genome Sciences, Inc. Human tumor necrosis factor receptors
US5654174A (en) * 1995-07-07 1997-08-05 Competitive Technologies, Inc. Herpes simplex virus glycoprotein D variants
US6291207B1 (en) * 1995-07-28 2001-09-18 Northwestern University Herpes virus entry receptor protein
EP0904278A4 (en) * 1996-03-22 1999-09-15 Human Genome Sciences Inc MOLECULE II INDUCER OF APOPTOSIS
US6479254B2 (en) * 1996-03-22 2002-11-12 Human Genome Sciences, Inc. Apoptosis inducing molecule II
WO1998003648A1 (en) * 1996-07-19 1998-01-29 Takeda Chemical Industries, Ltd. Fas ligand-like protein, its production and use
JP4090092B2 (ja) * 1996-07-19 2008-05-28 武田薬品工業株式会社 新規Fasリガンド様タンパク質およびそのDNA
BR9712670A (pt) * 1996-10-25 1999-10-19 Biogen Inc Receptores para linfotoxina-beta, anticorpos anti-receptor para linfotoxina, e anticorpos antiligante de linfotoxina como agentes terapêuticos para o tratamento de doencas imunológicas
WO1998018824A1 (en) * 1996-10-30 1998-05-07 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like 2
JP2001524985A (ja) * 1997-05-12 2001-12-04 スミスクライン・ビーチャム・コーポレイション ヒト腫瘍壊死因子受容体様2(tr2)抗体
US6346388B1 (en) * 1997-08-13 2002-02-12 Smithkline Beecham Corporation Method of identifying agonist and antagonists for tumor necrosis related receptors TR1 and TR2
US6051385A (en) * 1997-10-22 2000-04-18 The Regents Of The University Of Michigan Compositions and methods for identifying and testing therapeutics against HSV infection
AU2972199A (en) * 1998-02-20 1999-09-06 Reinhard Ebner Apoptosis inducing molecule ii and methods of use

Also Published As

Publication number Publication date
CA2296737C (en) 2012-07-03
US6140467A (en) 2000-10-31
ATE495240T1 (de) 2011-01-15
EP1003782B1 (en) 2011-01-12
CN1268953A (zh) 2000-10-04
CN1891714B (zh) 2011-06-22
AU8288298A (en) 1999-02-08
HK1026913A1 (en) 2000-12-29
EP1003782A1 (en) 2000-05-31
EP1003782A4 (en) 2002-07-10
AU741419B2 (en) 2001-11-29
WO1999002563A1 (en) 1999-01-21
KR20010021579A (ko) 2001-03-15
TWI222453B (en) 2004-10-21
DE69842096D1 (de) 2011-02-24
CA2296737A1 (en) 1999-01-21
KR100620334B1 (ko) 2006-09-13
CN1891714A (zh) 2007-01-10
JP2001509373A (ja) 2001-07-24

Similar Documents

Publication Publication Date Title
US6140467A (en) Ligand for herpes simplex virus entry mediator and methods of use
US6362325B1 (en) Murine 4-1BB gene
EP1887014B1 (en) Human toll homologues
US20110171242A1 (en) Ligand for herpes simplex virus entry mediator and methods of use
CA2292835A1 (en) Ntn-2 member of tnf ligand family
JP2000060580A (ja) Tnfの相同体tl5
US20030219860A1 (en) TRAIN-R: a cysteine rich member of the TNF-receptor family
CZ2000490A3 (cs) Interleukin-18-vazebné proteiny, příprava a použití
AU7713098A (en) Ntn-2 member of tnf ligand family
JPH10327878A (ja) 腫瘍壊死因子関連のレセプター、tr6
JP2003024085A (ja) 腫瘍壊死関連受容体tr7
WO2001079496A2 (en) Ligand for herpes simplex virus entry mediator and methods of use
WO1999026977A1 (en) Novel receptors opg-2
JPH1118786A (ja) 腫瘍壊死関連受容体tr7
US6998108B1 (en) Antibodies to p30 polypeptides and methods making and using same
EP1274840B1 (en) Ligand for herpes simplex virus entry mediator and methods of use
HK1026913B (en) Ligand for herpes simplex virus entry mediator and methods of use
AU2007201279B2 (en) Ligand for herpes simplex virus entry mediator and methods of use
WO2002074803A2 (en) Regulation of human icos v protein
AU2001253387A2 (en) Ligand for herpes simplex virus entry mediator and methods of use
CA2274803C (en) Receptor activator of nf-kappa b, receptor is member of tnf receptor superfamily

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050620

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050620

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080805

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20081029

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20081106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090205

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090303

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090522

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090529

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090903

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100810

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101210

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20110125

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110301

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110324

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees